Spravato (Esketamine) or Ketamine Denied by Insurance? How to Appeal

Treatment-resistant depression (TRD) is a serious, life-threatening condition — and two of the most promising treatments (Spravato/esketamine and IV ketamine) are among the most denied therapies by insurance companies. This guide explains how to fight back.

Spravato (Esketamine) vs. IV Ketamine: Insurance Coverage Landscape

Spravato (Esketamine Nasal Spray — Janssen/J&J)

FDA approvals:

• March 2019: Treatment-resistant depression (TRD) — in adults who have failed at least 2 antidepressants
• August 2020: Major depressive disorder with acute suicidal ideation or behavior (MDSI) — as a rapid-acting intervention

Spravato is the first FDA-approved esketamine product in the U.S. Because it has FDA approval for TRD and MDSI, insurance coverage arguments are strongest for Spravato.

Coverage reality: Many commercial plans cover Spravato with Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization. Medicaid coverage varies by state. Medicare Part B covers Spravato when administered in a registered REMS program as an in-office procedure.

IV Ketamine Infusions

IV ketamine for depression is not FDA-approved for this indication (it's approved for anesthesia). This makes coverage harder to obtain — insurers typically categorize it as "experimental/investigational" for depression.

However, growing evidence:

• NEJM 2019 (Murrough et al.): Ketamine shows rapid antidepressant effects within 24 hours
• JAMA 2022: IV ketamine comparable to ECT for TRD in head-to-head trial
• American Psychiatric Association Task Force on Esketamine (2017): Cautious support for ketamine use in carefully selected TRD patients

Many patients pursue IV ketamine because:

• Some psychiatrists prefer IV delivery to nasal spray
• Spravato is denied or not available locally
• Cost/access considerations

Appealing a Spravato Denial

"Not Medically Necessary" — Insufficient TRD Documentation

Spravato's FDA approval requires:

• Documented failure of at least 2 adequate antidepressant trials (different classes) of adequate dose and duration (≥ 6 weeks)
• Each trial should be documented with: drug name, dose, duration, and reason for discontinuation (lack of efficacy, not just side effects)

If your denial cites insufficient documentation:

• Provide a complete antidepressant trial history from your psychiatrist
• Include: medication name, starting dose, final dose, duration, outcome/reason for discontinuation
• Include severity scales: PHQ-9, QIDS-SR, HAMD-17 — showing severe, persistent depression

Minimum two-antidepressant-failure standard: Many plans use the FDA criteria (2 failed trials). Some plans require more (3–4 trials). Check your plan's specific criteria.

"Step Therapy Required"

If your insurer requires trying additional antidepressants before Spravato:

• Cite: additional antidepressant trials in TRD with established failure are unlikely to succeed. The APA has noted that each subsequent antidepressant trial in TRD has progressively lower response rates (STAR*D study: remission rates drop from 37% first-line to <15% by 4th-line)
• Document: "Additional step therapy would cause continued suffering and risk of suicide in a patient with established TRD who has failed [X] adequate antidepressant trials"

"Experimental/Investigational" Denial

For Spravato specifically:

• Spravato has FDA approval — the "experimental" argument fails entirely for the FDA-approved indication
• Cite the FDA approval date, indication, and TRANSFORM-1, TRANSFORM-2, SUSTAIN-1 trial data
• TRANSFORM-2 trial: Esketamine + new antidepressant vs. placebo + new antidepressant: 54% vs. 38% response rate (p=0.02) and 26% vs. 12% remission rate (p=0.006) at 4 weeks

MDSI (Suicidal Crisis) Indication

For the acute MDSI indication:

• Spravato is the first FDA-approved medication for imminent suicidal risk
• Urgent/expedited appeals are appropriate: "Delay in initiating esketamine treatment in a patient with active suicidal ideation poses a serious risk of harm or death"

Appealing an IV Ketamine Denial

IV ketamine is harder to appeal due to lack of FDA approval for depression. Arguments:

1. Failure of all FDA-approved options: STAR*D study data (Congress mandated CMS funded), ECT if contraindicated
2. "Emerging standard of care": APA and ACNP have issued statements recognizing ketamine's role in TRD
3. Life-threatening indication: Suicidal ideation requires aggressive treatment; benefit/risk favors ketamine when alternatives have failed
4. JAMA 2022 ECT-comparable data: IV ketamine head-to-head with ECT (the gold standard for TRD) showed non-inferiority
5. External Independent Review: Complete Guide" class="auto-link">External review: Request external IMR — independent reviewers are often more familiar with emerging evidence

Spravato REMS and Access Programs

Spravato is restricted by REMS (Risk Evaluation and Mitigation Strategy) — it must be administered in a certified healthcare setting where the patient is observed for 2 hours.

• Janssen CarePath: Janssen offers financial assistance programs for Spravato; visit JanssenCarePath.com
• CoverMyMeds: Assistance with prior authorization submissions for Spravato

Fight Back With ClaimBack

ClaimBack generates esketamine and ketamine denial appeal letters that cite FDA approval data, TRANSFORM trial evidence, STAR*D step-care failure, and APA guidelines.

Start your free Spravato/ketamine appeal at ClaimBack →

Related Reading

• Behavioral Health and Mental Health Parity: Your Appeal Rights
• What Is Medical Necessity (and How to Prove It)?
• How to Write an Insurance Appeal Letter